{"words": ["ocrelizumab", "ocrevus", "monoclonal", "antibody", "approved", "treatment", "multiple", "sclerosis", "eculizumab", "soliris", "approved", "several", "countries", "refractory", "forms", "generalized", "seropositive", "severe", "myasthenia", "gravis", "form", "gene", "therapy", "patisiran", "shown", "positive", "results", "transthyretin", "familial", "amyloidosis", "treatment", "headaches", "particularly", "migraines", "approaches", "shown", "interesting", "results", "criteria", "lewy", "body", "dementia", "revised", "generic", "use", "lamotrigine", "result", "recrudescence", "epileptic", "seizures", "adverse", "ocr\u00e9lizumab", "ocrevus", "un", "anticorps", "monoclonal", "\u00e9t\u00e9", "homologu\u00e9", "dans", "le", "traitement", "de", "la", "scl\u00e9rose", "en", "plaques", "l", "\u00e9culizumab", "soliris", "\u00e9t\u00e9", "approuv\u00e9", "dans", "plusieurs", "pays", "pour", "les", "formes", "r\u00e9fractaires", "de", "myasth\u00e9nie", "grave", "g\u00e9n\u00e9ralis\u00e9e", "s\u00e9ropositive", "une", "forme", "de", "th\u00e9rapie", "g\u00e9nique", "le", "patisiran", "montr\u00e9", "des", "r\u00e9sultats", "positifs", "dans", "l", "amylo\u00efdose", "\u00e0", "transthyr\u00e9tine", "dans", "le", "traitement", "des", "c\u00e9phal\u00e9es", "en", "particulier", "des", "migraines", "les", "approches", "non", "pharmacologiques", "ont", "montr\u00e9", "quelques", "avanc\u00e9es", "les", "crit\u00e8res", "de", "la", "d\u00e9mence", "\u00e0", "corps", "de", "lewy", "ont", "\u00e9t\u00e9", "r\u00e9vis\u00e9s", "l", "utilisation", "de", "g\u00e9n\u00e9riques", "de", "la", "lamotrigine", "n", "engendre", "pas", "de", "recrudescence", "de", "crises", "\u00e9pileptiques", "ni", "effets", "ind\u00e9sirables"], "authors": [["Chopard", "Isabelle", "I", "Service de neurologie, D\u00e9partement des neurosciences cliniques, CHUV, 1011 Lausanne."], ["Benninger", "David", "D", "Service de neurologie, D\u00e9partement des neurosciences cliniques, CHUV, 1011 Lausanne."], ["Demonet", "Jean-Fran\u00e7ois", "JF", "Service de neurologie, D\u00e9partement des neurosciences cliniques, CHUV, 1011 Lausanne."], ["Du Pasquier", "Renaud", "R", "Service de neurologie, D\u00e9partement des neurosciences cliniques, CHUV, 1011 Lausanne."], ["Hirt", "Lorenz", "L", "Service de neurologie, D\u00e9partement des neurosciences cliniques, CHUV, 1011 Lausanne."], ["Kuntzer", "Thierry", "T", "Service de neurologie, D\u00e9partement des neurosciences cliniques, CHUV, 1011 Lausanne."], ["Michel", "Patrik", "P", "Service de neurologie, D\u00e9partement des neurosciences cliniques, CHUV, 1011 Lausanne."], ["Nater", "Bernard", "B", "Service de neurologie, D\u00e9partement des neurosciences cliniques, CHUV, 1011 Lausanne."], ["Novy", "Jan", "J", "Service de neurologie, D\u00e9partement des neurosciences cliniques, CHUV, 1011 Lausanne."], ["Rossetti", "Andrea", "A", "Service de neurologie, D\u00e9partement des neurosciences cliniques, CHUV, 1011 Lausanne."], ["Rouaud", "Olivier", "O", "Service de neurologie, D\u00e9partement des neurosciences cliniques, CHUV, 1011 Lausanne."], ["Ryvlin", "Philippe", "P", "Service de neurologie, D\u00e9partement des neurosciences cliniques, CHUV, 1011 Lausanne."], ["Schluep", "Myriam", "M", "Service de neurologie, D\u00e9partement des neurosciences cliniques, CHUV, 1011 Lausanne."], ["Theaudin", "Marie", "M", "Service de neurologie, D\u00e9partement des neurosciences cliniques, CHUV, 1011 Lausanne."]], "title": "[Neurology].", "year": null, "sentences": ["Ocrelizumab (Ocrevus), an anti-CD20 monoclonal antibody, has been approved for the treatment of multiple sclerosis.", "Eculizumab (Soliris) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis.", "A form of gene therapy, patisiran, has shown positive results in transthyretin familial amyloidosis.", "In the treatment of headaches, particularly migraines, non-pharmacological approaches have shown some interesting results.", "The criteria for Lewy body dementia have been revised.", "Generic use of lamotrigine does not result in recrudescence of epileptic seizures or adverse effects.L\u2019ocr\u00e9lizumab (Ocrevus), un anticorps monoclonal anti-CD20, a \u00e9t\u00e9 homologu\u00e9 dans le traitement de la scl\u00e9rose en plaques.", "L\u2019\u00e9culizumab (Soliris) a \u00e9t\u00e9 approuv\u00e9 dans plusieurs pays pour les formes r\u00e9fractaires de myasth\u00e9nie grave g\u00e9n\u00e9ralis\u00e9e s\u00e9ropositive.", "Une forme de th\u00e9rapie g\u00e9nique, le patisiran a montr\u00e9 des r\u00e9sultats positifs dans l\u2019amylo\u00efdose \u00e0 transthyr\u00e9tine.", "Dans le traitement des c\u00e9phal\u00e9es, en particulier des migraines, les approches non pharmacologiques ont montr\u00e9 quelques avanc\u00e9es.", "Les crit\u00e8res de la d\u00e9mence \u00e0 corps de Lewy ont \u00e9t\u00e9 r\u00e9vis\u00e9s.", "L\u2019utilisation de g\u00e9n\u00e9riques de la lamotrigine n\u2019engendre pas de recrudescence de crises \u00e9pileptiques ni d\u2019effets ind\u00e9sirables."], "id": "29337452", "text": "Ocrelizumab (Ocrevus), an anti-CD20 monoclonal antibody, has been approved for the treatment of multiple sclerosis. Eculizumab (Soliris) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis. A form of gene therapy, patisiran, has shown positive results in transthyretin familial amyloidosis. In the treatment of headaches, particularly migraines, non-pharmacological approaches have shown some interesting results. The criteria for Lewy body dementia have been revised. Generic use of lamotrigine does not result in recrudescence of epileptic seizures or adverse effects.L\u2019ocr\u00e9lizumab (Ocrevus), un anticorps monoclonal anti-CD20, a \u00e9t\u00e9 homologu\u00e9 dans le traitement de la scl\u00e9rose en plaques. L\u2019\u00e9culizumab (Soliris) a \u00e9t\u00e9 approuv\u00e9 dans plusieurs pays pour les formes r\u00e9fractaires de myasth\u00e9nie grave g\u00e9n\u00e9ralis\u00e9e s\u00e9ropositive. Une forme de th\u00e9rapie g\u00e9nique, le patisiran a montr\u00e9 des r\u00e9sultats positifs dans l\u2019amylo\u00efdose \u00e0 transthyr\u00e9tine. Dans le traitement des c\u00e9phal\u00e9es, en particulier des migraines, les approches non pharmacologiques ont montr\u00e9 quelques avanc\u00e9es. Les crit\u00e8res de la d\u00e9mence \u00e0 corps de Lewy ont \u00e9t\u00e9 r\u00e9vis\u00e9s. L\u2019utilisation de g\u00e9n\u00e9riques de la lamotrigine n\u2019engendre pas de recrudescence de crises \u00e9pileptiques ni d\u2019effets ind\u00e9sirables.", "doi": null, "journal": ["Revue medicale suisse", "Rev Med Suisse"], "date": "2018-01-18_23:40:37"}